The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2181-2190

  Hao, Ming Xiu ^a   Jiang, Li Sheng ^a   Fang, Ning Yuan ^a   Pu, Jun ^a   Hu, Liu Hua ^a   Shen, Ling Hong ^a   Song, Wei ^a   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atherosclerosis; CB2 receptor; Inflammatory response; oxLDL; ROS; TNF

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; INFLAMMATION; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; METABOLISM; MOUSE; OXIDATIVE STRESS;

ANIMALS; BENZOXAZINES; CANNABINOIDS; CELL LINE; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MORPHOLINES; NAPHTHALENES; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA; CANNABINOID RECEPTOR MODULATORS;

EID: 77956806781     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M001511     Document Type: Article

References (44)

1. Steinberg, D., S. Parthasarathy, T. Carew, J. Khoo, and J. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
2. Holvoet, P., J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen. 1998. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98: 1487-1494.
3. Ogura, S., A. Kakino, Y. Sato, Y. Fujita, S. Iwamoto, K. Otsui, R. Yoshimoto, and T. Sawamura. 2009. LOX-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ. J. 73: 1993-1999.
4. Jiang, L. S., J. Pu, Z. H. Han, L. H. Hu, and B. He. 2009. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc. Res. 81: 805-813.
5. Liu, J., L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, Q. Gong, A. C. Chan, Z. Zhou, B. X. Huang, H. Y. Kim, et al. 2006. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA. 103: 13345-13350.
6. Bátkai, S., D. Osei-Hyiaman, H. Pan, O. El-Assal, M. Rajesh, P. Mukhopadhyay, F. Hong, J. Harvey-White, A. Jafri, G. Haskó, et al. 2007. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 21: 1788-1800.
7. Di Filippo, C., F. Rossi, S. Rossi, and M. D'Amico. 2004. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol. 75: 453-459.
8. Ashton, J. C., R. M. Rahman, S. M. Nair, B. A. Sutherland, M. Glass, and I. Appleton. 2007. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett. 412: 114-117.
9. Defer, N., J. Wan, R. Souktani, B. Escoubet, M. Perier, P. Caramelle, S. Manin, V. Deveaux, M. C. Bourin, A. Zimmer, et al. 2009. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 23: 2120-2130.
10. Han, K. H., S. Lim, J. Ryu, C. W. Lee, Y. Kim, J. H. Kang, S. S. Kang, Y. K. Ahn, C. S. Park, and J. J. Kim. 2009. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84: 378-386.
11. Bátkai, S., M. Rajesh, P. Mukhopadhyay, G. Haskó, L. Liaudet, B. F. Cravatt, A. Csiszár, Z. Ungvári, and P. Pacher. 2007. Decreased agerelated cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol. 293: H909-H918.
12. Shen, L. H., L. Zhou, B. Y. Wang, J. Pu, L. H. Hu, D. J. Chai, L. Wang, J. Z. Zeng, and B. He. 2008. Oxidized low-density lipoprotein induces differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Atherosclerosis. 199: 257-264.
13. Jones, B. G., P. A. Dickinson, M. Gumbleton, and I. W. Kellaway. 2002. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int. J. Pharm. 236: 65-79.
14. Chen, Y. H., S. J. Lin, J. W. Chen, H. H. Ku, and Y. L. Chen. 2002. Magnolol attenuates VCAM-1 expression in vitro in TNFalpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits. Br. J. Pharmacol. 135: 37-47.
15. Finkel, T., and N. J. Holbrook. 2000. Oxidants, oxidative stress and the biology of ageing. Nature. 408: 239-247.
16. Tedgui, A., and Z. Mallat. 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86: 515-581.
17. Landmesser, U., B. Hornig, and H. Drexler. 2004. Endothelial function: a critical determinant in atherosclerosis? Circulation. 109: II27-II33.
18. McCord, J. M. 1987. Oxygen-derived radicals: a link between reperfusion injury and inflammation. Fed. Proc. 46: 2402-2406.
19. Adams, I. B., and B. R. Martin. 1996. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 91: 1585-1614.
20. Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346: 561-564.
21. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterizaton of a peripheral receptor for cannabinoids. Nature. 365: 61-65.
22. Osei-Hyiaman, D., M. DePetrillo, P. Pacher, J. Liu, S. Radaeva, S. Ba'tkai, J. Harvey-White, K. Mackie, L. Offertáler, L. Wang, et al. 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115: 1298-1305.
23. Engeli, S., J. Bohnke, M. Feldpausch, K. Gorzelniak, J. Janke, S. Batkai, P. Pacher, J. Harvey-White, F. C. Luft, A. M. Sharma, et al. 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 54: 2838-2843.
24. Despres, J. P., A. Golay, and L. Sjostrom. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353: 2121-2134.
25. Van Gaal, L. F., A. M. Rissanen, A. J. Scheen, O. Ziegler, and S. Rossner. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 365: 1389-1397.
26. Pryce, G., Z. Ahmed, D. J. Hankey, S. J. Jackson, J. L. Croxford, J. M. Pocock, C. Ledent, A. Petzold, A. J. Thompson, G. Giovannoni, et al. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 126: 2191-2202.
27. Massa, F., G. Marsicano, H. Hermann, A. Cannich, K. Monory, B. F. Cravatt, G. L. Ferri, A. Sibaev, M. Storr, and B. Lutz. 2004. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113: 1202-1209.
28. Steffens, S., N. R. Veillard, C. Arnaud, G. Pelli, F. Burger, C. Staub, M. Karsak, A. Zimmer, J. L. Frossard, and F. Mach. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 434: 782-786.
29. Su, B., H. Dong, R. Ma, X. Zhang, Q. Ding, and L. Xiong. 2009. Cannabinoid 1 receptor mediation of spinal cord ischemic tolerance induced by limb remote ischemia preconditioning in rats. J. Thorac. Cardiovasc. Surg. 138: 1409-1416.
30. Zhang, M., B. R. Martin, M. W. Adler, R. K. Razdan, J. I. Jallo, and R. F. Tuma. 2007. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab. 27: 1387-1396.
31. Dagon, Y., Y. Avraham, G. Link, O. Zolotarev, R. Mechoulam, and E. M. Berry. 2007. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol. Dis. 27: 174-181.
32. Pacher, P., and G. Haskó. 2008. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 153: 252-262.
33. Montecucco, F., S. Lenglet, V. Braunersreuther, F. Burger, G. Pelli, M. Bertolotto, F. Mach, and S. Steffens. 2009. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J. Mol. Cell. Cardiol. 46: 612-620.
34. Hajrasouliha, A. R., S. Tavakoli, M. Ghasemi, P. Jabehdar-Maralani, H. Sadeghipour, F. Ebrahimi, and A. R. Dehpour. 2008. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur. J. Pharmacol. 579: 246-252.
35. Sheng, W. S., S. Hu, X. Min, G. A. Cabral, J. R. Lokensgard, and P. K. Peterson. 2005. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 49: 211-219.
36. Isachenko, E. G., T. I. Vitkina, and E. V. Berdyshev. 2004. Effect of the cannabinoid receptor ligand WIN-55,212-2 on the TNFalpha production by human mononuclear cells. Eksp. Klin. Farmakol. 67: 49-50.
37. Kim, S. H., S. J. Won, X. O. Mao, K. Jin, and D. A. Greenberg. 2005. Involvement of protein kinase A in cannabinoid receptor mediated protection from oxidative neuronal injury. J. Pharmacol. Exp. Ther. 313: 88-94.
38. Santini, E., R. Lupi, S. Baldi, S. Madec, D. Chimenti, E. Ferrannini, and A. Solini. 2008. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia. 51: 2117-2125.
39. Collins, T., and M. I. Cybulsky. 2001. NF-kappaB: pivotal mediator or innocent bystanderin atherogenesis? J. Clin. Invest. 107: 255-264.
40. Janssen-Heininger, Y. M., M. E. Poynter, and P. A. Baeuerle. 2000. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic. Biol. Med. 28: 1317-1327.
41. Flohe, L., R. Brigelius-Flohe, C. Saliou, M. G. Traber, and L. Packer. 1997. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med. 22: 1115-1126.
42. Bourcier, T., G. Sukhova, and P. Libby. 1997. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J. Biol. Chem. 272: 15817-15824.
43. Gertsch, J., M. Leonti, S. Raduner, I. Racz, J. Z. Chen, X. Q. Xie, K. H. Altmann, M. Karsak, and A. Zimmer. 2008. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA. 105: 9099-9104.
44. Gertsch, J. 2008. Anti-inflammatory cannabinoids in diet: towards a better understanding of CB(2) receptor action? Commun. Integr. Biol. 1: 26-28.